

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
LUX-VALVE PLUS SUCCESSFULLY COMPLETED THE FIRST
CLINICAL IMPLANTATION IN BRAZIL

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that recently, the first clinical implantation of LuX-Valve Plus, our proprietary transjugular tricuspid valve replacement product, has been successfully completed at Rede D’ OR Hospital in Brazil. The clinical interventional procedure was smooth. Immediately after the operation, it was shown that the implanted valve in the patient was stable, without regurgitation or paravalvular leakage, and additionally the mitral valve regurgitation had also been alleviated. The patient’s clinical performance, cardiac function and quality of life improved significantly after the operation. Professor Vincius Esteves, the cardiologist from Rede D’ OR Hospital, highly recognizes LuX-Valve Plus and its clinical interventional procedure process, commenting that this is the first application of transcatheter tricuspid valve intervention replacement in Latin America, and the successful application of LuX-Valve Plus would bring possibility of treatment of tricuspid valve regurgitation patients in Latin America. The success of the implantation demonstrates the wide applicability, high reliability, and simple operation process of LuX-Valve Plus.

The Company is in the process of facilitating its Lux-Valve product series to be approved by the National Medical Products Administration* (國家藥品監督管理局) in China for commercialization, its clinical trials for European CE marking and U.S. Food and Drug Administration registration. Meanwhile, the Company also continues to promote the global commercialization of this product and the realization of the Company’s internationalization strategy.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, February 28, 2024

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.

* *For identification purpose only*